Bayer recorded a 9.4% growth in Asia-Pacific Sales last year. With this increment Bayers Annual sales total reached 3.6 billion euros. The company said they are working their way to 11 billion euros by 2015. They are expecting 6 billion euros revenue from China by 2015.
Bayer us confident about its growth prospects in the region based on the dynamic development of the economy and the innovative potential of the pipeline. One of the best new performers is the clot-fighterÂ Xarelto, which grew 109% in the region last year in the hip-and-knee surgery market. With anticipated approvals for stroke prevention, Xarelto growth there is expected to accelerate.
Most drugmakers are now focused on emerging markets, given that developing countries are posting double-digit growth figures, compared with lagging growth in the U.S. and Europe. Bayer already sources almost one-third of its global sales in emerging countries.
Singapore, Vietnam & Pakistan reported a growth of over 26% in sales. China’s sales figures are kept confidential.
Monica Lessl, Head, Alliance Management, Global Innovation Sourcing, Bayer Healthcare, will be presenting at Pharma Partnering & Investment World Asia 2012 this March about "Analysing the business partnership models of mid – sized pharmas with Asian counterparts".